One shot gene therapy could end monthly eye injections for wet AMD
NCT ID NCT06825858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged 50 to 85 who previously responded to standard anti-VEGF therapy will receive a single dose to check safety and tolerability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kanghong Investigative Site
Phoenix, Arizona, 85016, United States
-
Kanghong Investigative Site
Lemont, Illinois, 60439, United States
-
Kanghong Investigative Site
Memphis, Tennessee, 38138, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a VR maze reveal hidden vision loss in macular degeneration?
- Can a new eye injection save vision in wet AMD?
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness